25 Oct, 2019 – Las Vegas, NV (October 25, 2019) – Evolve presented “Interim results of a novel 10% liquid intravenous immune globulin (IVIG) product’s Phase III Prospective, Open-Label Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics in Adults and Children with Primary Immunodeficiency Disease (PIDD)”. Abstracts available here.